Reviewer’s Comment: The updated 2-year analysis included an additional 17 events across both arms. There was also an overall decrease in early dropouts from a total of 174 (130 on the neratinib arm and 44 on the placebo arm) to 105 (80 on the neratinib arm and 25 on the placebo arm).